All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Poxvirus vaccine has proven effective in the treatment of breast and ovarian cancers
Medical expert of the article
Last reviewed: 23.04.2024
Recombinant poxvirus vaccine has proven effective in the treatment of metastatic breast cancer and ovarian cancer.
American scientists led by James Galli from the Laboratory of Immunology and Tumor Biology (National Cancer Institute) conducted a study of the effectiveness of the vaccine, in which 26 patients participated. Each month, they were vaccinated with the PANVAC vaccine containing the transgenes MUC-1, CEA and 3 T-cell co-stimulatory molecules
Before the study, all patients underwent treatment, 21 patients underwent chemotherapy three times. In 12 women with breast cancer, the time to progression was 2.5 months, and the overall survival was about 14 months. In 4 women, the disease was in remission. In 14 women with ovarian cancer, the mean time to onset of disease progression was about 2 months, and the overall survival was 15 months.
After conducting immunization courses with the vaccine, the most common side effect was the reaction at the injection site.
The authors intend to conduct a more extensive study that could adequately assess the effectiveness of such methods of cancer treatment.
[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13],